CN101897704B - 含有α-2肾上腺素能激动剂的组合物 - Google Patents
含有α-2肾上腺素能激动剂的组合物 Download PDFInfo
- Publication number
- CN101897704B CN101897704B CN200910247188.9A CN200910247188A CN101897704B CN 101897704 B CN101897704 B CN 101897704B CN 200910247188 A CN200910247188 A CN 200910247188A CN 101897704 B CN101897704 B CN 101897704B
- Authority
- CN
- China
- Prior art keywords
- adrenergic agonist
- component
- compositions
- divided
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 129
- 239000000384 adrenergic alpha-2 receptor agonist Substances 0.000 title abstract description 82
- 239000001768 carboxy methyl cellulose Substances 0.000 claims abstract description 26
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims abstract description 24
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims abstract description 23
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims abstract description 23
- IWEGDQUCWQFKHS-UHFFFAOYSA-N 1-(1,3-dioxolan-2-ylmethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CN(CC2OCCO2)N=C1 IWEGDQUCWQFKHS-UHFFFAOYSA-N 0.000 claims description 35
- 229960001724 brimonidine tartrate Drugs 0.000 claims description 35
- 239000007788 liquid Substances 0.000 claims description 23
- 230000002421 anti-septic effect Effects 0.000 claims description 19
- 229920000858 Cyclodextrin Polymers 0.000 claims description 18
- OSVXSBDYLRYLIG-UHFFFAOYSA-N dioxidochlorine(.) Chemical compound O=Cl=O OSVXSBDYLRYLIG-UHFFFAOYSA-N 0.000 claims description 11
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 11
- XTEGARKTQYYJKE-UHFFFAOYSA-M Chlorate Chemical class [O-]Cl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-M 0.000 claims description 7
- 239000000969 carrier Substances 0.000 claims description 7
- 239000004155 Chlorine dioxide Substances 0.000 claims description 5
- 235000019398 chlorine dioxide Nutrition 0.000 claims description 5
- 229910001919 chlorite Inorganic materials 0.000 claims description 5
- 229910052619 chlorite group Inorganic materials 0.000 claims description 5
- QBWCMBCROVPCKQ-UHFFFAOYSA-N chlorous acid Chemical compound OCl=O QBWCMBCROVPCKQ-UHFFFAOYSA-N 0.000 claims description 5
- 230000006641 stabilisation Effects 0.000 claims description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 3
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical class OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 claims description 3
- 230000000630 rising effect Effects 0.000 claims description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 3
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical class ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 claims description 2
- WGKMWBIFNQLOKM-UHFFFAOYSA-N [O].[Cl] Chemical compound [O].[Cl] WGKMWBIFNQLOKM-UHFFFAOYSA-N 0.000 claims 2
- 239000000048 adrenergic agonist Substances 0.000 abstract description 14
- 239000000556 agonist Substances 0.000 abstract description 2
- 230000002708 enhancing effect Effects 0.000 abstract 2
- 230000003381 solubilizing effect Effects 0.000 abstract 1
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 61
- -1 azatropylidene class Chemical class 0.000 description 29
- 238000001542 size-exclusion chromatography Methods 0.000 description 21
- 241001597008 Nomeidae Species 0.000 description 19
- 235000010443 alginic acid Nutrition 0.000 description 16
- 229920000615 alginic acid Polymers 0.000 description 16
- 239000002585 base Substances 0.000 description 15
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 14
- 239000003755 preservative agent Substances 0.000 description 13
- 230000002335 preservative effect Effects 0.000 description 13
- 229910052751 metal Inorganic materials 0.000 description 12
- 239000002184 metal Substances 0.000 description 12
- 229920000642 polymer Polymers 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 235000002639 sodium chloride Nutrition 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 229920001282 polysaccharide Polymers 0.000 description 11
- 239000005017 polysaccharide Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 229940072056 alginate Drugs 0.000 description 8
- 239000000539 dimer Substances 0.000 description 8
- 150000002148 esters Chemical class 0.000 description 8
- WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Chemical compound Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 239000000783 alginic acid Substances 0.000 description 7
- 229960001126 alginic acid Drugs 0.000 description 7
- 150000004781 alginic acids Chemical class 0.000 description 7
- 125000000129 anionic group Chemical group 0.000 description 7
- 125000001309 chloro group Chemical group Cl* 0.000 description 7
- 239000000178 monomer Substances 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 229920006321 anionic cellulose Polymers 0.000 description 6
- 229960003679 brimonidine Drugs 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 150000002500 ions Chemical class 0.000 description 6
- 238000005063 solubilization Methods 0.000 description 6
- 230000007928 solubilization Effects 0.000 description 6
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 description 5
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 5
- 239000001116 FEMA 4028 Substances 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 description 5
- 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 229960004853 betadex Drugs 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 150000004804 polysaccharides Chemical class 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 229920001661 Chitosan Polymers 0.000 description 4
- 229920002148 Gellan gum Polymers 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000002131 composite material Substances 0.000 description 4
- 235000010492 gellan gum Nutrition 0.000 description 4
- 239000000216 gellan gum Substances 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 229940054534 ophthalmic solution Drugs 0.000 description 4
- 239000002997 ophthalmic solution Substances 0.000 description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 description 4
- 239000013558 reference substance Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229940095064 tartrate Drugs 0.000 description 4
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 229920006318 anionic polymer Polymers 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000007900 aqueous suspension Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 235000010418 carrageenan Nutrition 0.000 description 3
- 229920001525 carrageenan Polymers 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 150000005829 chemical entities Chemical class 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 210000004087 cornea Anatomy 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 150000002978 peroxides Chemical class 0.000 description 3
- 125000000864 peroxy group Chemical group O(O*)* 0.000 description 3
- 238000006068 polycondensation reaction Methods 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- DZSVIVLGBJKQAP-UHFFFAOYSA-N 1-(2-methyl-5-propan-2-ylcyclohex-2-en-1-yl)propan-1-one Chemical compound CCC(=O)C1CC(C(C)C)CC=C1C DZSVIVLGBJKQAP-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 description 2
- AGBXYHCHUYARJY-UHFFFAOYSA-N 2-phenylethenesulfonic acid Chemical compound OS(=O)(=O)C=CC1=CC=CC=C1 AGBXYHCHUYARJY-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 2
- 102100022815 Alpha-2A adrenergic receptor Human genes 0.000 description 2
- 101710106858 Alpha-2A adrenergic receptor Proteins 0.000 description 2
- 102100036666 Alpha-2B adrenergic receptor Human genes 0.000 description 2
- 101710175728 Alpha-2B adrenergic receptor Proteins 0.000 description 2
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N D-Maltose Chemical group O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical group C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 2
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000000219 Sympatholytic Substances 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 2
- 230000001800 adrenalinergic effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 229910001413 alkali metal ion Inorganic materials 0.000 description 2
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 2
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 2
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000008365 aqueous carrier Substances 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 229960005069 calcium Drugs 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 150000003943 catecholamines Chemical class 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 2
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229960004716 idoxuridine Drugs 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- 150000002462 imidazolines Chemical class 0.000 description 2
- 125000001841 imino group Chemical group [H]N=* 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229920001206 natural gum Polymers 0.000 description 2
- 229940042880 natural phospholipid Drugs 0.000 description 2
- 230000000324 neuroprotective effect Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 150000004965 peroxy acids Chemical class 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- AVTYONGGKAJVTE-OLXYHTOASA-L potassium L-tartrate Chemical compound [K+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O AVTYONGGKAJVTE-OLXYHTOASA-L 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 230000003518 presynaptic effect Effects 0.000 description 2
- UIIIBRHUICCMAI-UHFFFAOYSA-N prop-2-ene-1-sulfonic acid Chemical compound OS(=O)(=O)CC=C UIIIBRHUICCMAI-UHFFFAOYSA-N 0.000 description 2
- 150000003252 quinoxalines Chemical class 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000003014 reinforcing effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000001593 sorbitan monooleate Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000000948 sympatholitic effect Effects 0.000 description 2
- BYJAVTDNIXVSPW-UHFFFAOYSA-N tetryzoline Chemical compound N1CCN=C1C1C2=CC=CC=C2CCC1 BYJAVTDNIXVSPW-UHFFFAOYSA-N 0.000 description 2
- 239000003451 thiazide diuretic agent Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- NLVXSWCKKBEXTG-UHFFFAOYSA-N vinylsulfonic acid Chemical compound OS(=O)(=O)C=C NLVXSWCKKBEXTG-UHFFFAOYSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- PCWPQSDFNIFUPO-VDQKLNDWSA-N (1S,3R,5R,6S,8R,10R,11S,13R,15R,16S,18R,20R,21S,23R,25R,26S,28R,30R,31S,33R,35R,36R,37S,38R,39S,40R,41S,42R,43S,44R,45S,46R,47S,48R,49S)-37,39,41,43,45,47,49-heptakis(2-hydroxyethoxy)-5,10,15,20,25,30,35-heptakis(hydroxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane-36,38,40,42,44,46,48-heptol Chemical compound OCCO[C@H]1[C@H](O)[C@@H]2O[C@H]3O[C@H](CO)[C@@H](O[C@H]4O[C@H](CO)[C@@H](O[C@H]5O[C@H](CO)[C@@H](O[C@H]6O[C@H](CO)[C@@H](O[C@H]7O[C@H](CO)[C@@H](O[C@H]8O[C@H](CO)[C@@H](O[C@H]1O[C@@H]2CO)[C@@H](O)[C@@H]8OCCO)[C@@H](O)[C@@H]7OCCO)[C@@H](O)[C@@H]6OCCO)[C@@H](O)[C@@H]5OCCO)[C@@H](O)[C@@H]4OCCO)[C@@H](O)[C@@H]3OCCO PCWPQSDFNIFUPO-VDQKLNDWSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- PQMFVUNERGGBPG-UHFFFAOYSA-N (6-bromopyridin-2-yl)hydrazine Chemical compound NNC1=CC=CC(Br)=N1 PQMFVUNERGGBPG-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- PRAMZQXXPOLCIY-UHFFFAOYSA-N 2-(2-methylprop-2-enoyloxy)ethanesulfonic acid Chemical compound CC(=C)C(=O)OCCS(O)(=O)=O PRAMZQXXPOLCIY-UHFFFAOYSA-N 0.000 description 1
- CUJVBAPGYBSBHJ-YWBSARSQSA-N 2-[[(1R,3R,5R,6S,8R,10R,11S,13R,15R,16S,18R,20R,21R,23R,25R,26R,28R,30R,31R,33R,35R,36R,37R,38R,39R,40R,41R,42R,43R,44R,45R,46R,47R,48R,49R)-36,38,40,42-tetrakis(carboxymethoxy)-10,15-bis(carboxymethoxymethyl)-37,39,41,43,44,45,46,47,48,49-decahydroxy-20,25,30,35-tetrakis(hydroxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontan-5-yl]methoxy]acetic acid Chemical compound OC[C@H]1O[C@@H]2O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCC(O)=O)O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCC(O)=O)O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCC(O)=O)O[C@@H]3[C@@H](CO)O[C@H](O[C@@H]4[C@@H](CO)O[C@H](O[C@@H]5[C@@H](CO)O[C@H](O[C@H]1[C@H](OCC(O)=O)[C@H]2O)[C@H](O)[C@H]5OCC(O)=O)[C@H](O)[C@H]4OCC(O)=O)[C@H](O)[C@H]3OCC(O)=O CUJVBAPGYBSBHJ-YWBSARSQSA-N 0.000 description 1
- JJJOZVFVARQUJV-UHFFFAOYSA-N 2-ethylhexylphosphonic acid Chemical compound CCCCC(CC)CP(O)(O)=O JJJOZVFVARQUJV-UHFFFAOYSA-N 0.000 description 1
- SQVSEQUIWOQWAH-UHFFFAOYSA-N 2-hydroxy-3-(2-methylprop-2-enoyloxy)propane-1-sulfonic acid Chemical compound CC(=C)C(=O)OCC(O)CS(O)(=O)=O SQVSEQUIWOQWAH-UHFFFAOYSA-N 0.000 description 1
- IBZYPBGPOGJMBF-UHFFFAOYSA-N 3,6 anhydrogalactose Natural products CCC=CCC1C(CC(=O)NC(C(C)CC)C(O)=O)CCC1=O IBZYPBGPOGJMBF-UHFFFAOYSA-N 0.000 description 1
- WZYRMLAWNVOIEX-BGPJRJDNSA-N 3,6-anhydro-D-galactose Chemical compound O=C[C@H](O)[C@H]1OC[C@@H](O)[C@@H]1O WZYRMLAWNVOIEX-BGPJRJDNSA-N 0.000 description 1
- DCQFFOLNJVGHLW-UHFFFAOYSA-N 4'-Me ether-Punctatin+ Natural products O1C(O)C(O)C2OCC1C2O DCQFFOLNJVGHLW-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- DHSSDEDRBUKTQY-UHFFFAOYSA-N 6-prop-2-enyl-4,5,7,8-tetrahydrothiazolo[4,5-d]azepin-2-amine Chemical compound C1CN(CC=C)CCC2=C1N=C(N)S2 DHSSDEDRBUKTQY-UHFFFAOYSA-N 0.000 description 1
- JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical class C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 241001147468 Chondrus ocellatus Species 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241001269524 Dura Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical group OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- WDZVGELJXXEGPV-YIXHJXPBSA-N Guanabenz Chemical compound NC(N)=N\N=C\C1=C(Cl)C=CC=C1Cl WDZVGELJXXEGPV-YIXHJXPBSA-N 0.000 description 1
- INJOMKTZOLKMBF-UHFFFAOYSA-N Guanfacine Chemical compound NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl INJOMKTZOLKMBF-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- YNUSXBGNHIRIBN-UHFFFAOYSA-N N1C(CCC1)=O.N1C=CC(C1)=O Chemical compound N1C(CCC1)=O.N1C=CC(C1)=O YNUSXBGNHIRIBN-UHFFFAOYSA-N 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- CQXADFVORZEARL-UHFFFAOYSA-N Rilmenidine Chemical compound C1CC1C(C1CC1)NC1=NCCO1 CQXADFVORZEARL-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 241000790234 Sphingomonas elodea Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000006177 alkyl benzyl group Chemical group 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical group OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 150000003868 ammonium compounds Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N anhydrous guanidine Natural products NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- MMCPOSDMTGQNKG-UHFFFAOYSA-N anilinium chloride Chemical compound Cl.NC1=CC=CC=C1 MMCPOSDMTGQNKG-UHFFFAOYSA-N 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- IEJXVRYNEISIKR-UHFFFAOYSA-N apraclonidine Chemical compound ClC1=CC(N)=CC(Cl)=C1NC1=NCCN1 IEJXVRYNEISIKR-UHFFFAOYSA-N 0.000 description 1
- 229960002610 apraclonidine Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical class [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 description 1
- 229940052299 calcium chloride dihydrate Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229920003090 carboxymethyl hydroxyethyl cellulose Polymers 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000007766 cera flava Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- WZYRMLAWNVOIEX-UHFFFAOYSA-N cinnamtannin B-2 Natural products O=CC(O)C1OCC(O)C1O WZYRMLAWNVOIEX-UHFFFAOYSA-N 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- JXMXDKHEZLKQPB-UHFFFAOYSA-N detomidine Chemical compound CC1=CC=CC(CC=2[N]C=NC=2)=C1C JXMXDKHEZLKQPB-UHFFFAOYSA-N 0.000 description 1
- 229960001894 detomidine Drugs 0.000 description 1
- HRLIOXLXPOHXTA-NSHDSACASA-N dexmedetomidine Chemical compound C1([C@@H](C)C=2C(=C(C)C=CC=2)C)=CN=C[N]1 HRLIOXLXPOHXTA-NSHDSACASA-N 0.000 description 1
- 229960004253 dexmedetomidine Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- CDMADVZSLOHIFP-UHFFFAOYSA-N disodium;3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane;decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].O1B([O-])OB2OB([O-])OB1O2 CDMADVZSLOHIFP-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- DUYCTCQXNHFCSJ-UHFFFAOYSA-N dtpmp Chemical compound OP(=O)(O)CN(CP(O)(O)=O)CCN(CP(O)(=O)O)CCN(CP(O)(O)=O)CP(O)(O)=O DUYCTCQXNHFCSJ-UHFFFAOYSA-N 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 229960004553 guanabenz Drugs 0.000 description 1
- 229960002048 guanfacine Drugs 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229940027278 hetastarch Drugs 0.000 description 1
- FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000030214 innervation Effects 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940050906 magnesium chloride hexahydrate Drugs 0.000 description 1
- DHRRIBDTHFBPNG-UHFFFAOYSA-L magnesium dichloride hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[Cl-].[Cl-] DHRRIBDTHFBPNG-UHFFFAOYSA-L 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- HRLIOXLXPOHXTA-UHFFFAOYSA-N medetomidine Chemical compound C=1C=CC(C)=C(C)C=1C(C)C1=CN=C[N]1 HRLIOXLXPOHXTA-UHFFFAOYSA-N 0.000 description 1
- 229960002140 medetomidine Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- 229960005016 naphazoline Drugs 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000010399 physical interaction Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 229960002816 potassium chloride Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- ROSDSFDQCJNGOL-UHFFFAOYSA-N protonated dimethyl amine Natural products CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960000764 rilmenidine Drugs 0.000 description 1
- 229910052701 rubidium Inorganic materials 0.000 description 1
- IGLNJRXAVVLDKE-UHFFFAOYSA-N rubidium atom Chemical compound [Rb] IGLNJRXAVVLDKE-UHFFFAOYSA-N 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002356 skeleton Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- PFUVRDFDKPNGAV-UHFFFAOYSA-N sodium peroxide Chemical compound [Na+].[Na+].[O-][O-] PFUVRDFDKPNGAV-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 210000000331 sympathetic ganglia Anatomy 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 229960000337 tetryzoline Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- QQJLHRRUATVHED-UHFFFAOYSA-N tramazoline Chemical compound N1CCN=C1NC1=CC=CC2=C1CCCC2 QQJLHRRUATVHED-UHFFFAOYSA-N 0.000 description 1
- 229960001262 tramazoline Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- AQLJVWUFPCUVLO-UHFFFAOYSA-N urea hydrogen peroxide Chemical compound OO.NC(N)=O AQLJVWUFPCUVLO-UHFFFAOYSA-N 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/734—Alginic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
本发明涉及用于提高α-2-肾上腺素能激动剂组分的有效性的组合物,其含有载体组分、α-2-肾上腺素能激动剂组分、有助于增溶α-2-肾上腺素能激动剂组分的升高溶解度组分。在一个实施方式中,α-2-肾上腺素能激动剂组分包括α-2-肾上腺素能激动剂。在另一实施方式中,升高溶解度组分包括羧甲基纤维素。
Description
本申请是申请日为2001年7月9日,申请号为01807339.5的、发明名称和本发明相同的发明专利申请的分案申请。
有关申请的交叉参考
本申请请求以2000年7月14日提交的美国临时专利申请60/218,200为优先权。
发明背景
本发明涉及含有α-2-肾上腺素能激动剂组分的组合物。更加具体地,本发明涉及这样的组合物,其中所述的α-2-肾上腺素能激动剂组分在治疗有效浓度下具有增高的溶解度。
α-2-肾上腺素能激动剂包括化学实体,例如化合物、离子、复合物等,其有效作用于或结合α-2-肾上腺素能受体并产生治疗效果。α-2-肾上腺素能激动剂组分是指激动剂本身及其所有前体、其代谢产物和它们的联合形式。含有α-2-肾上腺素能激动剂组分的配制组合物的一种连续刺激可以使此类组分更加有效。例如,α-2-肾上腺素能激动剂在液体组合物中常常因可溶于该组合物的液态载体中而受益。这样的溶解度易于均匀和精确给药。
而且,分配或给予的α-2-肾上腺素能激动剂组分应该优先溶解在生物体系或环境中,例如,用于有效或提高体内经细胞膜或脂质双层的扩散作用。一些具有较高pKa,例如大于约7的α-2-肾上腺素能激动剂组分,倾向于在接近其pKa的pH值下非常容易快速穿过脂质膜,因为在这种环境中它们在中性至碱性生物环境那大多数未电离。然而,一些此类α-2-肾上腺素能激动剂组分在这些至碱性生物pH下不溶解。这种不溶性可以减弱膜扩散性能,致使α-2-肾上腺素能激动剂组分在指定剂量下低效和/或改变其治疗效果。此外,溶解的α-2-肾上腺素能激动剂组分具有其他益处,譬如,减小对与α-2-肾上腺素能激动剂组分相互作用的组织的刺激作用。
始终需要新的含有α-2-肾上腺素能激动剂组分的组合物。
发明概述
已经发现了新的含α-2-肾上腺素能激动剂组分的组合物。本发明的组合物含有某些物质,其有效地至少是协助或者有助于α-2-肾上腺素能激动剂组分增溶到该组合物中,并且优选溶解在组合物所施用或引入的环境中,例如人眼。更加可取地,本发明的α-2-肾上腺素能激动剂组分的增溶作用促进该组合物转运穿过脂质膜。另外,这样的增溶作用适宜为药物的更加可靠和可重现剂型提供了准备。而且,业已发现了含α-2-肾上腺素能激动剂组分的组合物,其含有具有显著优越性的防腐剂,例如降低与α-2-肾上腺素能激动剂组分和/或与施用该组合物的患者之间的相关作用,同时保持防腐有效性。
本发明的组合物优选通过提高α-2-肾上腺素能激动剂组分的表观水溶度来增强α-2-肾上腺素能激动剂组分的有效性,优选在高于中性的pH下。本发明的组合物除了含有肾上腺素能激动剂组分以外,还含有有效量的升高溶解度组分(SECs)以提高α-2-肾上腺素能激动剂组分的溶解度。更加可取地,与不含有SECs的相似组合物比较,α-2-肾上腺素能激动剂组分更加易溶于具有例如pH等于或高于7的本发明组合物中。在另一实施方案中,与α-2-肾上腺素能激动剂组分在不含有SECs的相似组合物对比,本发明组合物的α-2-肾上腺素能激动剂组分更加易溶于中性,优选碱性的,组合物所施用的生物环境中。
在一个实施方式中,α-2-肾上腺素能激动剂组分包括亚氨基-咪唑啉类、咪唑啉类、咪唑类、氮杂卓类、噻嗪类、唑啉类、胍类、儿茶酚胺类化合物,它们的生物相容性盐和酯和混合物。更加可取地,α-2-肾上腺素能激动剂组分包括喹喔啉类组分。喹喔啉类组分包括喹喔啉、其生物相容性盐、其酯、其其他衍生物等,和它们的混合物。喹喔啉类衍生物的非限定实例包括(2-咪唑啉(imidozolin)-2-基氨基)喹喔啉、5-溴-6-(2-咪唑啉-2-基氨基)喹喔啉,和其生物相容性盐和其酯,优选5-溴-6-(2-咪唑啉-2-基氨基)喹喔啉的酒石酸盐等,及其混合物。此后,5-溴-6-(2-咪唑啉-2-基氨基)喹喔啉的酒石酸盐被称作“酒石酸溴莫尼定”。
在一个优选的实施方式中,α-2-肾上腺素能激动剂组分,例如上述那些,对α-2A-肾上腺素能受体、α-2B-肾上腺素能受体和/或α-2D-肾上腺素能受体具有特异性。
在一个实施方式中,α-2-肾上腺素能激动剂组分在该组合物中未电离。更加可取地,α-2-肾上腺素能激动剂组分在组合物所施用的生物环境中也未电离。
在一个有效实施方式中,SEC包括多阴离子组分。在此所用的术语“多阴离子组分”是指化学实体,例如,电离带电物质,如电离带电的聚合物,其包括一个以上的离散阴离子电荷,也就是多个离散的阴离子电荷。更加可取地,聚阴离子组分选自具有多阴离子电荷的聚合物,和它们的混合物。
特别有效的多阴离子组分选自:由丙烯酸衍生的阴离子聚合物(是指包括丙烯酸、丙烯酸酯等及其混合物衍生的聚合物),由甲基丙烯酸衍生的阴离子聚合物(是指包括甲基丙烯酸、甲基丙烯酸酯等及其混合物衍生的聚合物),由藻酸衍生的聚合物(是指包括藻酸、藻酸盐等及其混合物),氨基酸的阴离子聚合物(是指包括氨基酸、氨基酸盐等及其混合物的聚合物)等,和它们的混合物。非常有效的多阴离子组分是选自阴离子纤维素类衍生物及其混合物的那些,尤其是羧甲基纤维素。
多阴离子组分适宜具有足够的阴离子以相互作用或者影响,特别是提高α-2-肾上腺素能激动剂组分的溶解度。该相互作用优选足以使α-2-肾上腺素能激动剂组分在治疗有效浓度下基本上完全溶解。SEC在所述组合物中的含量优选是约0.1%(w/v)-约30%(w/v),更优选约0.2%(w/v)-约10%(w/v),并且特别更优选约0.2%(w/v)-约0.6%(w/v)。
该组合物包括载体组分,例如,含水液体载体组分。在一个实施方式中,该组合物具有约7或更高的pH,优选约7-约9,并且是眼科可接受的。
在一个优选实施方式中,提供了一种组合物,其包括有效量的向施用组合物的患者提供至少一种治疗益处的α-2-肾上腺素能激动剂组分、有效量的提高α-2-肾上腺素能激动剂组分的溶解度的阴离子纤维素衍生物和含水液体载体组分。α-2-肾上腺素能激动剂组分优选含有5-溴-6-(2-咪唑啉-2-基氨基)喹喔啉的酒石酸盐。阴离子纤维素衍生物优选含有羧甲基纤维素。阴离子纤维素衍生物在该组合物中的浓度应该是约0.2%(w/v)-约0.6%(w/v)。
在一个优选实施方式中,本发明的组合物是眼科可接受的,例如该 组合物不具有有损于施用该组合物的人体或动物的有害或有毒性质。
在本发明的一个广义方面中,在所述组合物中形成复合物。在另一实施方式中,复合物包括由至少一个喹喔啉组分衍生的单体单元。在一个优选实施方式中,本发明的组合物是二聚体。在特别优选的实施方式中,复合物具体是酒石酸溴莫尼定的二聚体的复合物。
在本发明的另一广义方面,提供了含有α-2-肾上腺素能激动剂组分和有效量的至少有助于组合物防腐的防腐剂组分的组合物。优选地,防腐组分包括氧-氯组分,例如化合物、离子、复合物等,它们生物上可接受,化学上稳定并且基本上或者明显没有对组合物中的α-2-肾上腺素能激动剂组分或施用该组合物的患者产生不利影响。所述的组合物适宜基本上在组合物和施用该组合物的患者中不含有环糊精。
本发明所述的任何特征和特征联合包括在本发明的范围内内,条件是任何联合的特征不会相互矛盾和脱离上下文、本说明书和所属领域普通技术人员的常识。
本发明的其他优越性和方面在下面详述和权利要求书中更加清楚。
附图简述
图1是在不同羧甲基纤维素浓度下可溶性酒石酸溴莫尼定对pH的图形。
发明详述
提供含有α-2-肾上腺素能激动剂组分和SECs的组合物。本发明组合物中的α-2-肾上腺素能激动剂组分更加可溶且可以更加有效地作为治疗剂使用。本发明组合物中所用的SECs可以有效地增强电离的α-2-肾上腺素能激动剂组分、非电离的α-2-肾上腺素能激动剂组分或两者的增溶作用。本发明的组合物包括液体载体组分并具有液体的特性,例如,含水液体、溶液。
更加可取地,与不含有SECs的相似组合物中相同α-2-肾上腺素能激动剂组分在相当浓度下比较,α-2-肾上腺素能激动剂组分在pH大于7的本发明组合物中具有增高的溶解度。优选地,与不含SECs的相似组合物中相当浓度的相同α-2-肾上腺素能激动剂组分比较,α-2-肾上腺素能激动剂组分在pH范围为约7-约10的本发明组合物中 具有增高的溶解度。
不希望受到任何任何理论或作用机理的限制,可以确信增溶的α-2-肾上腺素能激动剂组分相对于未增溶的α-2-肾上腺素能激动剂组分能够更好地穿过脂质膜。还可以相信,增溶的α-2-肾上腺素能激动剂组分在物理上更小,因此在物理上更加容易渗透或扩散经过脂质膜。
在一个实施方式中,本发明的SECs能够使α-2-肾上腺素能激动剂组分以治疗有效浓度增溶到其所引入的生物环境中。更加可取地,引入本发明组合物的生物环境具有约7-约9的pH范围。譬如,含有SEC和α-2-肾上腺素能激动剂组分的组合物可以施用到眼睛的角膜,其具有约7的pH,其中α-2-肾上腺素能激动剂组分基本上溶解在给药区域。而且,在一个实施方式中,α-2-肾上腺素能激动剂组分通过SECs增溶在给药区域比未经SECs增溶的α-2-肾上腺素能激动剂组分更加容易扩散穿过生物脂质膜。α-2-肾上腺素能激动剂组分的增溶作用适当减少了敏感组织在与α-2-肾上腺素能激动剂组分接触或相互作用时的刺激作用。
本发明所用的α-2-肾上腺素能激动剂组分选自可以受益于SECs的存在的那些。一般地,由于SECs的存在使α-2-肾上腺素能激动剂组分具有增高的表观溶度,优选增高的表观水溶度。
α-2-肾上腺素能激动剂组分的实例包括含胺的分子。优选地,α-2-肾上腺素能激动剂组分是pH大于约7,更优选约7-约9的含胺分子。
α-2-肾上腺素能激动剂组分包括α-2-肾上腺素能激动剂。在此所用的术语“α-2-肾上腺素能激动剂”包括化学实体,例如化合物、离子、复合物等,它们产生净交感神经阻滞反应,导致调节增强,例如通过结合交感神经节后神经末梢上的突触前α-2受体或者结合平滑肌细胞上的神经节后α-2受体。交感神经阻滞反应特征在于抑制、减小或阻止交感神经***传送的脉冲作用。本发明的α-2-肾上腺素能激动剂组分结合突触前的α-2-肾上腺素能受体,引起负反馈减少神经元去甲肾上腺素的释放。此外,它们还作用于神经节后的α-2-肾上腺素能受体,抑制β-肾上腺素能受体刺激的环AMP的形成,其除了其他细胞内途径上的神经节后α-2-肾上腺素能受体的作用以外,还导致睫状肌松弛。对于神经节前或神经节后α-2-肾上腺素能受体的作用造成肾 上腺素影响减弱。减弱的肾上腺素影响导致胆碱能神经支配所致的收缩增强。α-2-肾上腺素能激动剂还包括具有神经保护作用的化合物。例如,5-溴-6-(2-咪唑啉-2-基氨基)喹喔啉是一种α-2-肾上腺素能激动剂,其通过未知机理具有神经保护活性。
本发明不受所列具体基团和化合物的限制,下列是适用于本发明的代表性α-2-肾上腺素能激动剂:亚氨基-咪唑啉类化合物,包括可乐定、阿普尼定;咪唑啉类化合物,包括萘甲唑啉、希美唑啉(xymetazoline)、四氢唑啉和曲马唑啉;咪唑类化合物,包括地托咪定、美托咪定、右美托咪定;氮杂卓类化合物,包括B-HT920(6-烯丙基-2-氨基-5,6,7,8-四氢-4H-噻唑[4,5-d]-氮杂卓和B-HT933;噻嗪类化合物,包括赛拉嗪;唑啉类化合物,包括利美尼定;胍类化合物,包括胍那苄和胍法辛;儿茶酚胺;等及其衍生物。
特别有效的α-2-肾上腺素能激动剂包括喹喔啉组分。在一个实施方式中,该喹喔啉组分包括喹喔啉、其衍生物及其混合物。更加优选地,喹喔啉的衍生物包括5-卤化物-6-(咪唑啉-2-基氨基)喹喔啉。5-卤化物-6-(2-咪唑啉-2-基氨基)喹喔啉的“卤化物”可以是氟化物、氯化物、碘化物,或者优选溴化物,形成5-溴-6-(2-咪唑啉-2-基氨基)喹喔啉。更加优选,本发明使用的喹喔啉的衍生物包括5-溴-6-(2-咪唑啉-2-基氨基)喹喔啉的酒石酸盐,或者酒石酸溴莫尼定。
其他有效的喹喔啉衍生物是公知的。譬如,有效的喹喔啉衍生物包括Burke等在美国专利号5,703,077中公开的化合物。还参见Danielwicz等的3,890,319。Burke等和Danielwiez各自的内容分别在此引入作为参考。
喹喔啉及其衍生物,例如酒石酸溴莫尼定,含有胺并且优选具有大于7的pKa,优选是7.5-9。
具有α-2-肾上腺素能激动剂作用的上述化合物的类似物也明确地属于本发明范围内。
更加优选地,α-2-肾上腺素能激动剂,例如上述物质,有效激活α-2A-肾上腺素能受体、α-2B-肾上腺素能受体和α-2D-肾上腺素能受体。
在一个实施方式中,α-2-肾上腺素能激动剂,例如酒石酸溴莫尼 定,在所述的组合物中基本上未电离。在另一实施方式中,所述的肾上腺素能化合物在其所施用的环境中,例如角膜中,基本上未电离。不希望受到任何理论和作用机理的约束,可以相信,肾上腺素能化合物的未电离形式刺激其穿过膜脂质双层的渗透作用。
本发明可以采用任何适当的SEC。在一个实施方式中,SECs包括吡咯烷酮(pyrrolinidone)组分。吡咯烷酮组分的实例包括聚乙烯吡咯烷酮类化合物及其衍生物。在一个优选实施方式中,SECs包括多阴离子组分。有效的多阴离子组分包括,但不限于,那些可以有效提高难溶α-2-肾上腺素能激动剂组分的表观溶度,优选水溶解度和/或增强α-2-肾上腺素能激动剂组分的稳定性和/或减少α-2-肾上腺素能激动剂组分的不利副作用的物质。此外,优选多阴离子组分在使用浓度下是眼科可接受的。此外,多阴离子组分适宜包括三(3)或多种阴离子(或负)电荷。在多阴离子组分是聚合物的情况中,优选该聚合物的各个重复单元包括离散的阴离子电荷。特别适用的阴离子组分是那些溶于水的阴离子组分,例如,以使用浓度溶解在目前使用的液体含水介质中,例如含有α-2-肾上腺素能激动剂组分的液体含水介质。
优选多阴离子组分具有足够的阴离子与α-2-肾上腺素能激动剂组分相互作用。这种相互作用被希望能够增溶α-2-肾上腺素能激动剂组分和/或保持该α-2-肾上腺素能激动剂组分溶解在载体组分中,例如液体介质中。
多阴离子组分还包括一种或多种具有多个阴离子电荷的聚合物。实例包括:
羧甲基淀粉金属
羧甲基羟乙基淀粉金属,
水解的聚丙烯酰胺和聚丙烯腈
肝素
一种或多种下列的均聚物和共聚物:
丙烯酸和甲基丙烯酸
丙烯酸金属盐和甲基丙烯酸金属盐
藻酸
藻酸金属盐
乙烯磺酸
乙烯磺酸金属盐
氨基酸类,例如天门冬氨酸、谷氨酸等
氨基酸的金属盐
对苯乙烯磺酸
对苯乙烯磺酸金属盐
2-甲基丙烯酰氧基乙基磺酸
2-甲基丙烯酰氧基乙基磺酸金属盐
3-甲基丙烯酰氧基-2-羟丙基磺酸
3-甲基丙烯酰氧基-2-羟丙基磺酸金属盐
2-丙烯酰胺-2-甲基丙烷磺酸
2-丙烯酰胺-2-甲基丙烷磺酸金属盐
烯丙基磺酸
烯丙基磺酸金属盐等。
在另一实施方式中,多阴离子组分包括阴离子多糖,其在较高pH下,例如约7和更高的pH下,倾向于以电离形式存在。下列是本发明可以使用的阴离子多糖的一些实例。
多右旋糖是右旋糖的随机结合的缩合聚合物,哺乳动物只能够代谢其一部分。该聚合物可以含有微量的结合山梨醇、柠檬酸和葡萄糖。
硫酸软骨素也称作硫酸软骨素钠,其是在人体组织的各个部分都可以发现的粘多糖,特别是在软骨、骨骼、腱、韧带和血管壁。从鲨鱼的软骨可以提取和纯化得到这种多糖。
角叉菜胶是一种具有重复半乳糖单元和3,6-脱水半乳糖单元的直链多糖,这两种单元可以硫酸化或者未硫酸化,它们通过交替的1-3和β1-4键连接。角叉菜胶是一种水胶体,从多种红色海藻和角叉菜可以热提取到角叉菜胶。
麦芽糖糊精是水溶性葡萄糖聚合物,其通过淀粉与酸和/或酶在水存在下的反应而形成。
发现适用于本发明的其他阴离子多糖是亲水性胶体物质并且包括天然树胶,例如吉兰糖胶,藻酸盐胶,即藻酸的铵和碱金属盐及其混合物。此外,可以使用壳聚糖,其是脱乙酰壳多糖的常用名。壳多糖是一种含有多-(N-乙酰基-D-葡糖胺)的天然产物。吉兰糖胶是由多沼假单胞菌(pseudomonas elodea)的发酵产生胞外杂多糖来制备的。藻酸盐 和壳聚糖可以使用得自Protan,Inc,Commaek,N.Y的干粉。吉兰糖胶可以是Kelco Division of Merk & Co.,Inc,San Diego,Calif的产品。
通常,藻酸盐可以是任何水溶性藻酸盐,包括碱金属藻酸盐,例如藻酸的钠、钾、锂、铷和铯盐,和铵盐,和有机碱的可溶性藻酸盐,例如一-、二-或三-乙醇胺藻酸盐,藻酸苯胺盐等。一般地,基于组合物的总重量计,使用约0.2%-约1%(重量)的吉兰糖胶、藻酸盐或壳聚糖离子型多糖来获得本发明的凝胶组合物。
更加可取地,所述的阴离子多糖是环状的。更优选,该环化阴离子多糖包括少于10个单体单元。特别更优选,该环化多糖包括少于6个多糖单元。
在一个实施方式中,特别适用的环化阴离子多糖包括环糊精类。环糊精类的实例包括,但不限于:α-环糊精,α-环糊精的衍生物,β-环糊精,β-环糊精的衍生物,γ-环糊精,γ-环糊精的衍生物,羧甲基-β-环糊精,羧甲基-乙基-β-环糊精,二乙基-β-环糊精,二甲基-β-环糊精,甲基-β-环糊精,无规甲基-β-环糊精、葡糖基-β-环糊精,麦芽糖基-β-环糊精,羟乙基-β-环糊精,羟丙基-β-环糊精,磺丁基醚-β-环糊精等及其混合物。磺丁基醚-β-环糊精是本发明优选的环化阴离子多糖。优选给予包括上述环糊精在内的SEC,其在本发明中在所用的浓度下对哺乳动物、人体无毒,从而抑制这种掺混。在此所用的与环糊精有关的术语“衍生物”是指任何被取代或者改性的化合物,其具有环糊精的特定化学结构足以起到环糊精组分的作用,例如提高活性成分的溶解度和/或稳定性和/或减小活性成分的不良副作用和/或与所述的活性成分形成包合复合物。
虽然环糊精和/或其衍生物可以用作SECs,本发明的一个实施方式可以包括除环糊精和/或其衍生物之外的SECs。
特别适用和优选种类的多阴离子组分包括阴离子纤维素衍生物。阴离子纤维素衍生物包括金属羧甲基纤维素、金属羧甲基羟乙基纤维素和羟丙基甲基纤维素及其衍生物。
本发明的多阴离子组分常常可以未电离状态存在,例如,以固体状态,以伴生或抗衡离子的联合形式,特别是数目上与离散阴离子电荷数相同的多个离散阳离子,使未电离多阴离子组分在电学上呈中性。例如,本发明的未电离多阴离子组分可以以酸形式存在和/或以与一种或多种 金属的联合形式存在。由于多阴离子组分优选是眼科可接受的,优选与未电离多阴离子组分关联的金属在所用的浓度下是眼科可接受的。特别适用的金属包括碱金属,如钠和钾;碱土金属,如钙和镁,和它们的混合物。钠非常适合在未电离多阴离子组分中提供抗衡离子。本发明可以使用以未电离态与除H+的阳离子和金属阳离子结合的多阴离子组分。
本发明组合物中的SEC的含量不是十分重要,只要α-2-肾上腺素能激动剂组分的溶解度至少多少有所增高并以生物可接受的量存在。该含量应该有效完成在本发明组合物中和/或给予人体和动物后的预期功能。在一个实施方式中,SEC(优选多阴离子组分)的含量足以与至少大部分量的,并且更优选基本上全部量的,α-2-肾上腺素能激动剂组分复合,在一个实施方案中,本发明组合物中的多阴离子组分的含量是该组合物的约0.1%-约30%(w/v)和更高。优选地,多阴离子组分的含量在约0.2%(w/v)-约10%(w/v)内。更优选,多阴离子组分的含量在约0.2%(w/v)-约0.6%(w/v)内。甚至更优选,多阴离子组分是羧甲基纤维素并以约0.2%(w/v)-约0.6%(w/v)存在于所述组合物中。羧甲基纤维素在本发明组合物的特别有效的浓度是约0.5%。
在一个实施方式中,SECs例如羧甲基纤维素有助于α-2-肾上腺素能激动剂组分增溶在组合物中。虽然SECs能够协助电离的α-2-肾上腺素能激动剂组分的增溶作用,但优选本发明中使用的SECs有助于未电离的α-2-肾上腺素能激动剂组分的增溶作用。譬如,在一个实施方式中,羧甲基纤维素可以协助增溶电离的α-2-肾上腺素能激动剂组分。在另一实施方式中,羧甲基纤维素协助电离的酒石酸溴莫尼定增溶到该组合物中。更优选,羧甲基纤维素有助于未电离的酒石酸溴莫尼定增溶到该组合物中。
在一个实施方式中,所述的组合物还可以含有一种或多种防腐剂组分,其有助于组合物的防腐。选择的防腐剂组分在本发明组合物中是显著且有效的防腐剂,也就是说在多阴离子组分的存在下,当把组合物施用给人体或动物时适宜具有低毒性并且更优选没有毒性。
当在增溶剂存在下使用时药物组合物中常用的防腐剂或有助于组合物防腐的组分常常降低有效性。在某些情况中,通过使用增量的防腐剂可以补偿这种降低了的防腐功效。然而,当涉及敏感或柔弱的机体组织时,这种途径可能不适用,因为防腐剂本身可以在适用该组合物的人 体或动物中引起一些副作用或者敏感性。
更加可取地,有助于组合物,特别是其中α-2-肾上腺素能激动剂组分防腐的本发明防腐剂组分,在小于约1%(w/v)或约0.8%(w/v)的浓度下有效并且可以等于或小于500ppm(w/v),例如在约10ppm(w/v)-约200ppm(w/v)的范围内。本发明的防腐剂组分适宜包括,但不限于,那些以小于苯扎氯铵的程度与多阴离子组分形成复合物的防腐剂。
本发明防腐剂组分的非常适用的实例包括,但不限于氧化性防腐组分,如氧-氯组分、过氧化物、过酸盐、过酸等,和它们的混合物。用本发明防腐剂的氧-氯组分的具体实例包括次氯酸盐组分,如次氯酸盐类;氯酸盐组分,例如氯酸盐类;高氯酸盐组分,例如高氯酸盐类;和亚氯酸盐组分。亚氯酸盐组分的实例包括稳定化的二氧化氯(SCD),次氯酸金属盐,如碱金属和碱土金属次氯酸盐等,和它们的混合物。技术等级(或USP等级)的次氯酸钠是非常有效的防腐组分。人们不十分了解许多次氯酸盐组分如SCD的精确化学组合物。某些次氯酸盐组分的制造或生产描述在McNicholas美国专利3,278,447中,其在此引入作为参考。适用SCD产品的具体实例包括Rio Linda Chemical Company,Inc以商标Dura Klor和由International Dioxide,Inc.以商标Anthium Dioxide出售的产品。特别适用的SCD是Allergan,Inc.以商标PuriteTM出售的产品。氧化性防腐剂组分的其他实例包括过氧组分。譬如,痕量的过氧组分用过氧化氢稳定剂稳定化,例如二亚乙基三胺五(亚甲基膦酸)或1-羟基乙叉基-1,1-二膦酸,可以作为防腐剂用于眼环境使用的组分内。另外,实际上可以使用任何过氧组分,只要其在水中水解产生过氧化氢,其提供有效量的过氧化氢,包括过硼酸钠十水合物、过氧化钠和过氧化脲。已经发现过乙酸,有机过氧化合物,可能无法用本发明的体系稳定化。例如,参见,Martin等的美国专利号5,725,887,其内容在此全文引入作为参考。
组合物中可以含有除氧化性防腐剂组分以外的防腐剂。防腐剂的选择可能取决于给药的途径。适合组合物的防腐剂通过一种途径给药时可能具有有害性质,但通过另一种途径给药可以排除这种有害性质。对于鼻和眼用组合物,优选防腐剂含有季铵化合物,特别是烷基苄基二甲基铵化合物的混合物并且公知的是“苯扎氯铵”。然而,对于通过吸入给药的组合物,优选的防腐剂是三氯叔丁醇等。其他可以使用的防腐剂, 特别是用于直肠给药的组合物的防腐剂,例如是甲基、乙基、丙基、丁基酯和以商品名“Nipastat”出售的产品。
在本发明的另一广义方面,提供的组合物含有α-2-肾上腺素能激动剂组分、有效量的至少有助于防腐的防腐剂组分,优选是有效防腐量。更加可取地,防腐剂组分包括氧-氯组分,如化合物、离子、复合物等,其(1)基本上不或者不显著有损于组合物中的α-2-肾上腺素能激动剂组分或者施用该组合物的患者。和(2)基本上是生物上可接受的和化学上稳定的。本发明的组合物含有α-2-肾上腺素能激动剂组分、氧-氯组分和液体载体组分,并且优选基本上不含有环糊精。
适用于本发明的载体组分选择是对本发明的组合物无毒且基本上没有有害作用。在一个实施方式中,载体组分是液体载体。在一个优选实施方式中,载体组分是液体含水载体组分。特别适用的含水液体载体是由盐水衍生的,例如普通盐水溶液或常规缓冲盐水溶液。该含水液体载体优选pH约6-约9或约10,更优选约6-约8,并且特别优选约7.5。液体介质优选具有眼科可接受的张力水平,例如至少约200mOsmol/g,更优选约200-约400mOsmol/kg。在一个特别适用的实施方式中,载体组分的重量摩尔渗透压浓度或张力基本上相当于眼睛特别是人眼的流体的张力。
在一个实施方式中,含有SECs和α-2-肾上腺素能激动剂组分的载体组分在25℃下可以具有大于0.01厘泊(cps)的粘度,优选在25℃下粘度大于约1cps,甚至更优选在25℃下大于约10cps。在一个优选实施方式中,所述的组合物在25℃下具有约50cps的粘度并含有常规缓冲盐水溶液,羧甲基纤维素和酒石酸溴莫尼定。
为了确保含水液体载体组分的pH,并且由此使组合物的pH,保持在预期范围内,该含水液体载体组分可以含有至少一种缓冲剂组分。虽然任何适当的缓冲剂组分都可以使用,优选选择那些不产生大量二氧化氯或产生大量气体如CO2的组分。优选缓冲剂组分是无机的。本发明优选使用碱金属和碱土金属缓冲剂组分。
可以使用任何一种或多种适当的眼科可接受张力组分,条件是该组分与液体含水载体组分的其他成分相容且不对本发明组合物所施用的人体或动物具有有害或毒性性质。优选张力组分的实例包括氯化钠、氯化钾、甘露醇、右旋糖、甘油、丙二醇及其混合物。在一个实施方式中, 张力组分选自无机盐及其混合物。
本发明的组合物一般可以作为溶液或混悬液存在于含水液体或非水液体中,或作为水包油或油包水液体乳液。本发明的组合物可以含有一种或多种附加组分如稀释剂、矫味剂、表面活性剂、增稠剂、润滑剂等,例如,该附加组分是同类型组合物中常用的那些。
水混悬液形式的本发明组合物可以含有适合制备水混悬液的赋形剂。此类赋形剂是助悬剂,例如羧甲基纤维素钠、甲基纤维素、羟丙基甲基纤维素、藻酸钠、聚乙烯吡咯烷酮、黄芪胶和***胶;分散或湿润剂可以是天然磷脂,例如卵磷脂;和环氧乙烷与长链脂族醇如十七碳亚乙基氧基鲸蜡醇的缩聚产物,或者环氧乙烷与由脂肪酸和己糖醇衍生的偏酯的缩聚产物如聚氧化乙烯山梨糖醇一油酸酯,或者环氧乙烷与由脂肪酸和己糖醇酐衍生的偏酯的缩聚产物,例如聚氧化乙烯脱水山梨糖醇一油酸酯等及其混合物。此类水混悬液还可以含有一种或多种着色剂、一种或多种矫味剂和一种或多种甜味剂,如蔗糖、糖精等及其混合物。
油形式的本发明组合物可以在植物油中配制,例如橄榄油、芝麻油或椰子油,或在矿物油如液体石蜡中。所述的混悬液可以含有增稠剂,例如蜂蜡、硬石蜡或鲸蜡醇。可以加入甜味剂,如上述那些,和矫味剂来提供可口的口腔制剂。
本发明的组合物还可以是水包油乳液。油相可以是植物油,例如液体石蜡,等等及其混合物。适当的乳化剂可以是天然树胶,例如***胶或黄芪胶,天然磷脂,例如大豆油卵磷脂,和由脂肪酸和己糖醇酐衍生的酯和偏酯,例如脱水山梨糖醇一油酸酯,该乳液还可以含有甜味剂和矫味剂。
糖浆和酏剂形式的本发明组合物可以用甜味剂配制,例如如上所述的。此类制剂还可以含有缓和剂,和矫味剂和着色剂。
任何具体人或动物的具体剂量水平取决于多种因素,包括所用活性成分的活性、年龄、体重、全身健康、性别、饮食、给药时间、给药途径、***速率、药物联合形式和被治疗具体病症的严重性。
在本发明的一个广义方面,在本发明组合物中形成复合物。在一个实施方式中,复合物含有至少一种喹喔啉组分的单体单元。喹喔啉组分的实例包括喹喔啉、(2-咪唑啉-2-基氨基)喹喔啉、5-溴-6-(2- 咪唑啉-2-基氨基)喹喔啉、其盐、其酯、其其他衍生物等,及其混合物。例如,在一个实施方式中,本发明的复合物可以含有5-溴-6-(2-咪唑啉-2-基氨基)喹喔啉单体单元的偶联物。在另一实施方式中,复合物可以含有5-溴-6-(2-咪唑啉-2-基氨基)喹喔啉单体单元与酒石酸溴莫尼定单体单元的偶联物。
在一个优选实施方式中,本发明的复合物是二聚体。例如,本发明的二聚体可以含有喹喔啉和5-溴-6-(2-咪唑啉-2-基氨基)喹喔啉。优选地,本发明的二聚体包括两个酒石酸溴莫尼定单体单元。
不希望受到任何理论或作用机理的限制,相信任何过氧化物生成剂或者强氧化剂如氧化性防腐剂组分,例如氧-氯组分、过氧化物、过酸盐、过酸类等及其混合物可以促进复合物的形成,更适宜于α-2-肾上腺素能激动剂组分的复合物。譬如,据信酒石酸溴莫尼定单体单元的二聚体在亚氯酸盐,优选稳定化的二氧化氯存在时形成。
而且,相信可以包括单体之间的相互作用,其将单体或单体亚基保持在一起形成复合物,优选低聚物和更优选二聚体,但不限于,共价键、离子键、疏水性键、静电键、氢键、其他化学和/或物理相互作用,等及其联合形式。此类复合物可以在液体中分离,例如,含水液体、介质。在一个实施方式中,单体或单体亚基通过非共价键方式保持在一起。在一个实施方式中,单体或单体亚基通过静电键或力保持在一起。
下列非限定实施例举例说明本发明的某些方面。
实施例1
酒石酸溴莫尼定具有约7.78的pKa。0.5%(w/v)酒石酸溴莫尼定在一种制剂眼科溶液中的pH-溶解度曲线在23℃下建立在约5-约8的范围内。表1。可以相信可以使用非0.5%的肾上腺素能激动剂的浓度,只要它们具有治疗活性。另外,例如温度可以改变,溶解度曲线可以在37℃(98.6°F)下进行。通过首先将聚乙烯醇(PVA)溶解在水中制备制剂赋形剂。将PVA加入到约1/3的所需总量的纯水中同时恒定搅拌。搅拌该浆液20-30分钟且随后加热至80-95℃同时搅拌。在达到80-90℃之后1小时内撤去混合物的热源并且再搅拌10分钟保证均匀性(部分I)。除酒石酸溴莫尼定以外,将眼科溶液的其他组分溶解在含有1/3所需总量的纯水的单独容器内(部分II)。随后用数个漂洗体积的纯水将 PVA混合物(部分I)定量转移到部分II中。用纯水调整溶液至最终体积,无需调节pH。
称量酒石酸溴莫尼定的重量且转移到含有5mL上述制剂赋形剂的10mL试管内。各样本的pH随后用稀氢氧化钠和/或稀盐酸调整至预定值。将样本置于搅拌平板的搁物架中且以高速搅拌2天获得均匀混合物;将搁物架于搅拌平板分开防止热量从搅拌平板扩散到样本。通过研究监测试验的温度且发现是23±1℃。
在搅拌2天结束时,测定各个样本的pH值,随后将约1mL的各样本置于微量离心管(聚丙烯)中且在4000rpm下离心10分钟。经1μm过滤单元(Whatman,13mm,PTFE)过滤该上清液。弃去第一个3-4滴;收集其余的滤液且用HPLC流动相定量稀释。稀释样本随后直接注射到HPLC柱(Dupont Zorbax,250mmx4.6mm,5μm)用于分析酒石酸溴莫尼定,从而定量分析酒石酸溴莫尼定的含量。在pH6.3-6.5的制剂载体中制备10.05%酒石酸溴莫尼定的对照品并且在分析之前(未处理)和之后(处理过)离心和过滤。由此评估酒石酸溴莫尼定样本制备的两个步骤中的潜在损失。为了确保重现性,连续数天重复进行研究。
表I.含0.5%酒石酸溴莫尼定的眼科溶液
酒石酸溴莫尼定在制剂赋形剂中的溶解度数据如表II所示。结果表明,酒石酸溴莫尼定的溶解度是高度依赖于pH的且在5-8的pH范围中相差2个数量级以上。溶解度随着pH增高急剧降低。对于处理的和未处理的对照品结果非常接近,表示离心和过滤不会引起任何酒石酸溴莫尼定的显著损失。连续数天获得的磷脂溶解度曲线彼此吻合。表II.酒石 酸溴莫尼定在pH为5-8的眼科溶液中的溶解度
a搅拌2天之后且在取样离心和过滤之前测量
b表示基于样本重量的理论浓度。样本溶液澄清表明所有酒石酸溴莫尼定已经溶解。
c离心和过滤步骤之前对照品中酒石酸溴莫尼定的浓度
d离心和过滤步骤之后对照品中酒石酸溴莫尼定的浓度
e%w/v
实施例2
测定含有SECs和氧-氯组分的组合物(溶液)中的酒石酸溴莫尼定的pH-溶解度曲线。具体而言,在不同pH条件下测定羧甲基纤维素(CMC)钠。用酒石酸溴莫尼定试验的CMC的不同浓度是0%,0.056%,0.17%,0.5%,1.5%(w/v),表II。
试验样本还含有等渗组分、缓冲剂组分和稳定化的二氧化氯(PuriteTM),表III。羧甲基纤维素钠、氯化钠、氯化钾、氯化钙二水合物和氯化镁六水合物是USP级。硼酸和硼酸钠十水合物是NF级。
表III
a Allergan,Inc以商标PuriteTM出售。
各样本(1-5)的pH在约7-约10。将含有样本溶液的瓶子置于实验室旋转器中且放置在室温下平衡15天(~21℃)。用孔径为0.45μm的25mm直径聚砜纤维素乙酸酯注射型滤器过滤钙样本溶液。用过滤的溶液分析酒石酸溴莫尼定。
用常规HPLC和检测技术来检测和测定可溶性酒石酸溴莫尼定的浓度。表IV。在各个CMC浓度下相对于pH绘制溶解度。试验数据点用非线性最小二乘法(Deltagraph4.0版DeltaPoint,Inc.)与改进的Henderson-Hasselbalch方程吻合,图2。R2值显示试验值和理论方程式之间的吻合的良好性好于0.991。
表IV
图1清楚地表明,酒石酸溴莫尼定的溶解度随着CMC浓度的增高而增大。例如,在pH7.5下,含有0%CMC的样本是酒石酸溴莫尼定为1000ppm;0.056%CMC,1300ppm;0.17%CMC,1300ppm;和0.5%,1600ppm。在pH7.5下,含1.5%CMC的样本得到约1400ppm,其小于含0.5%CMC的相似溶液。不清楚在这点得到这种观察结果的原因。然而,与不含有CMC的溶液相比,酒石酸溴莫尼定更加易溶于含1.5%CMC的溶液。
CMC也可以有效地使酒石酸溴莫尼定增溶到生物环境中,例如角膜的生物环境。
实施例3
酒石酸溴莫尼定二聚体
将酒石酸溴莫尼定加入到装有含次氯酸盐的组合物的试管内。令试管平衡10天。分析取自试管的样本。观察到一部分的酒石酸溴莫尼定单体单元偶联成为二聚体。
虽然本发明描述了有关的多种具体实施例和实施方式,应理解本发明不受其限制且在下面权利要求书中的范围内可以有不同的实施方式。
Claims (4)
1.一种治疗上有效的含水眼科组合物,含有:
酒石酸溴莫尼定,
所述组合物包含0.2%w/v-0.6%w/v的升高溶解度组分,所述升高溶解度组分是羧甲基纤维素或羧甲基纤维素钠,
所述组合物不合有环糊精,且所述的组合物具有防腐剂,所述防腐剂为氧-氯复合物,所述氧-氯复合物选自:次氯酸盐类,氯酸盐类,高氯酸盐类和亚氯酸盐组分;
含水液体载体;
并具有6.67-10的pH。
2.权利要求1的组合物,其中含有1000ppm的酒石酸溴莫尼定。
3.权利要求1的组合物,其具有pH7.5。
4.权利要求1的组合物,其中所述亚氯酸盐组分为稳定化的二氧化氯。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21820000P | 2000-07-14 | 2000-07-14 | |
US60/218200 | 2000-07-14 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB018073395A Division CN100569291C (zh) | 2000-07-14 | 2001-07-09 | 含有α-2肾上腺素能激动剂的组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101897704A CN101897704A (zh) | 2010-12-01 |
CN101897704B true CN101897704B (zh) | 2014-10-29 |
Family
ID=22814143
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB018073395A Expired - Lifetime CN100569291C (zh) | 2000-07-14 | 2001-07-09 | 含有α-2肾上腺素能激动剂的组合物 |
CN200910247188.9A Expired - Lifetime CN101897704B (zh) | 2000-07-14 | 2001-07-09 | 含有α-2肾上腺素能激动剂的组合物 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB018073395A Expired - Lifetime CN100569291C (zh) | 2000-07-14 | 2001-07-09 | 含有α-2肾上腺素能激动剂的组合物 |
Country Status (20)
Country | Link |
---|---|
US (4) | US6627210B2 (zh) |
EP (1) | EP1365811A2 (zh) |
JP (3) | JP4927298B2 (zh) |
KR (1) | KR100757656B1 (zh) |
CN (2) | CN100569291C (zh) |
AR (1) | AR033539A1 (zh) |
AU (2) | AU2001273269B2 (zh) |
BR (1) | BR0109317A (zh) |
CA (1) | CA2402405C (zh) |
HK (1) | HK1060519A1 (zh) |
HU (1) | HUP0303197A3 (zh) |
IL (2) | IL151530A0 (zh) |
MX (1) | MXPA02008930A (zh) |
NO (1) | NO333367B1 (zh) |
NZ (1) | NZ521185A (zh) |
PL (1) | PL360707A1 (zh) |
RU (1) | RU2311928C2 (zh) |
TW (1) | TWI287998B (zh) |
WO (1) | WO2002005853A2 (zh) |
ZA (1) | ZA200207413B (zh) |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001273269B2 (en) * | 2000-07-14 | 2005-08-11 | Allergan, Inc. | Compositions containing alpha-2-adrenergic agonist components |
JP2004503593A (ja) * | 2000-07-14 | 2004-02-05 | アラーガン、インコーポレイテッド | 増大した溶解度を持つ治療活性成分を含む組成物 |
US20050026924A1 (en) * | 2000-07-14 | 2005-02-03 | Allergan, Inc. | Compositions containing alpha-2-adrenergic agonist components |
AU2011250793B2 (en) * | 2000-07-14 | 2012-11-29 | Allergan, Inc. | Compositions containing alpha-2-adrenergic agonist components |
US8858961B2 (en) | 2000-07-14 | 2014-10-14 | Allergan, Inc. | Compositions containing alpha-2-adrenergic agonist components |
US20040214829A1 (en) * | 2000-07-14 | 2004-10-28 | Allergan, Inc. | Compositions containing alpha-2-adrenergic agonist components |
EP1390073A2 (en) * | 2001-05-03 | 2004-02-25 | Allergan, Inc. | Compositions having enhanced pharmacokinetic characteristics |
US20020198209A1 (en) | 2001-05-03 | 2002-12-26 | Allergan Sales Inc. | Compositions having enhanced pharmacokinetic characteristics |
US6753017B2 (en) * | 2001-11-07 | 2004-06-22 | Jrs Pharma Lp | Process for preparing dry extracts |
US7030149B2 (en) * | 2002-04-19 | 2006-04-18 | Allergan, Inc. | Combination of brimonidine timolol for topical ophthalmic use |
US7642258B2 (en) * | 2002-04-19 | 2010-01-05 | Allergan, Inc. | Combination of brimonidine and timolol for topical ophthalmic use |
US6982079B2 (en) * | 2002-04-26 | 2006-01-03 | Allergan, Inc. | Compositions for treating hyperemia |
US20040266776A1 (en) * | 2003-06-25 | 2004-12-30 | Gil Daniel W. | Methods of preventing and reducing the severity of stress-associated conditions |
ATE380551T1 (de) * | 2002-10-08 | 2007-12-15 | Allergan Inc | Verwendung von brimonidine zur behandlung von dementia und morbus parkinson |
MXPA05003664A (es) * | 2002-10-08 | 2005-06-08 | Allergan Inc | Agonistas del adrenoceptor alfa 2b o 2b/2c para tratamiento de neurodegeneracion. |
US20040137079A1 (en) * | 2003-01-08 | 2004-07-15 | Cook James N. | Contact lens and eye drop rewetter compositions and methods |
US20040191332A1 (en) * | 2003-03-27 | 2004-09-30 | Allergan, Inc. | Preserved ophthalmic compositions |
US7439241B2 (en) | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
EP1654002B2 (en) | 2003-08-07 | 2014-01-29 | Allergan, Inc. | Compositions for delivery of therapeutics into the eyes |
WO2005041869A2 (en) * | 2003-10-24 | 2005-05-12 | Josef Rettenmaier & Soehne Gmbh & Co., Kg | Process for co-spray drying agents with dry silicified mcc |
US8529927B2 (en) * | 2004-04-30 | 2013-09-10 | Allergan, Inc. | Alpha-2 agonist polymeric drug delivery systems |
US20050244469A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
US7993634B2 (en) | 2004-04-30 | 2011-08-09 | Allergan, Inc. | Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods |
US7799336B2 (en) | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
US20050244463A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
US8425929B2 (en) * | 2004-04-30 | 2013-04-23 | Allergan, Inc. | Sustained release intraocular implants and methods for preventing retinal dysfunction |
US8673341B2 (en) * | 2004-04-30 | 2014-03-18 | Allergan, Inc. | Intraocular pressure reduction with intracameral bimatoprost implants |
US9498457B2 (en) | 2004-04-30 | 2016-11-22 | Allergan, Inc. | Hypotensive prostamide-containing biodegradable intraocular implants and related implants |
US8722097B2 (en) | 2004-04-30 | 2014-05-13 | Allergan, Inc. | Oil-in-water method for making polymeric implants containing a hypotensive lipid |
CA2505836C (en) * | 2004-05-06 | 2013-08-27 | Alcon Inc. | Topical brimonidine tartrate formulations that lack chlorine dioxide |
CN101426502A (zh) * | 2004-05-25 | 2009-05-06 | 桑斯罗萨医药发展公司 | 治疗或预防炎症性皮肤疾病的化合物、制剂及方法 |
JP4789454B2 (ja) * | 2004-12-03 | 2011-10-12 | 株式会社キーエンス | 蛍光顕微鏡 |
US20060228487A1 (en) * | 2005-04-11 | 2006-10-12 | J. Rettenmaier & Söehne GmbH + Co. KG | Methods of combining active agents with augmented microcrystalline cellulose |
US8003624B2 (en) * | 2005-08-25 | 2011-08-23 | Schering Corporation | Functionally selective ALPHA2C adrenoreceptor agonists |
RU2008110902A (ru) * | 2005-08-25 | 2009-09-27 | Шеринг Корпорейшн (US) | Агонисты адренорецепторов альфа а2с |
PE20070336A1 (es) * | 2005-08-25 | 2007-04-16 | Schering Corp | Compuestos de indolina como agonistas de receptores adrenergicos alfa2c funcionalmente selectivos |
US7700592B2 (en) * | 2005-08-25 | 2010-04-20 | Schering Corporation | α2C adrenoreceptor agonists |
EP1956906A4 (en) | 2005-11-09 | 2009-12-30 | Combinatorx Inc | METHODS, COMPOSITIONS AND KITS FOR THE TREATMENT OF PATHOLOGIES |
US20070238732A1 (en) * | 2006-04-10 | 2007-10-11 | Allergan, Inc. | Brimonidine and timolol compositions |
US8969415B2 (en) * | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
AU2009214028B2 (en) * | 2008-02-15 | 2014-06-12 | Bone Therapeutics | Pharmaceutical composition for use in the treatment and/or the prevention of osteoarticular diseases |
WO2009101210A1 (en) * | 2008-02-15 | 2009-08-20 | Bone Therapeutics | Pharmaceutical composition for use in the treatment or prevention of osteoarticular diseases |
US7842714B2 (en) * | 2008-03-03 | 2010-11-30 | Allergan, Inc. | Ketorolac tromethamine compositions for treating ocular pain |
US9192571B2 (en) | 2008-03-03 | 2015-11-24 | Allergan, Inc. | Ketorolac tromethamine compositions for treating or preventing ocular pain |
US20100197694A1 (en) * | 2008-08-01 | 2010-08-05 | Gerald Horn | Compositions and methods for treatment of diseases and conditions with increased vascular permeability |
US20110003823A1 (en) * | 2008-08-01 | 2011-01-06 | Alpha Synergy Development, Inc. | Compositions and methods for treatment of diseases and conditions associated with vasodilation and/or vascular leakage |
EP2320911B1 (en) * | 2008-08-01 | 2014-10-08 | Eye Therapies LLC | Vasoconstriction compositions and methods of use |
US8952011B2 (en) | 2008-08-01 | 2015-02-10 | Eye Therapies Llc | Compositions and methods for the treatment of nasal conditions |
US20120156244A1 (en) * | 2008-08-01 | 2012-06-21 | Alpha Synergy Development Inc. | Nasal Compositions and Uses Thereof |
US20100203165A1 (en) | 2008-08-01 | 2010-08-12 | Gerald Horn | Compositions and methods for treatment of disorders or conditions of the eye |
US20100202979A1 (en) * | 2008-08-01 | 2010-08-12 | Gerald Horn | Compositions and methods for treatment of pulmonary diseases and conditions |
EP2323734A1 (en) * | 2008-08-04 | 2011-05-25 | Schering Corporation | Cyclopropylchromene derivatives as modulators of the alpha-2c receptor |
EP2356106A1 (en) | 2008-10-07 | 2011-08-17 | Schering Corporation | Biaryl spiroaminooxazoline analogues as alpha2c adrenergic receptor modulators |
US20110293549A1 (en) | 2009-02-03 | 2011-12-01 | Athena Cosmetics, Inc. | Composition, method and kit for enhancing hair |
US8987270B2 (en) | 2009-07-27 | 2015-03-24 | Eye Therapies Llc | Formulations of selective alpha-2 agonists and methods of use thereof |
EP3421030A1 (en) | 2009-11-09 | 2019-01-02 | Allergan, Inc. | Compositions and methods for stimulating hair growth |
CA2782872A1 (en) * | 2009-12-17 | 2011-06-23 | Alpha Synergy Development, Inc. | Compositions and methods for ophthalmic delivery of nasal decongestants |
US9522153B2 (en) | 2009-12-22 | 2016-12-20 | Allergan, Inc. | Compositions and methods for lowering intraocular pressure |
WO2011091205A2 (en) | 2010-01-22 | 2011-07-28 | Allergan, Inc. | Intracameral sustained release therapeutic agent implants |
US8513247B2 (en) | 2010-03-26 | 2013-08-20 | Galderma Laboratories, L.P. | Methods and compositions for safe and effective treatment of erythema |
US8445526B2 (en) | 2011-02-03 | 2013-05-21 | Glaucoma & Nasal Therapies Llc | Compositions and methods for treatment of glaucoma |
US9744168B2 (en) | 2011-10-19 | 2017-08-29 | Galderma Laboratories, Inc. | Method of reducing facial flushing associated with systemic use of phosphodiesterase type 5 inhibitors |
JP6511401B2 (ja) | 2013-02-15 | 2019-05-15 | アラーガン、インコーポレイテッドAllergan,Incorporated | 持続型薬物送達インプラント |
US8999938B2 (en) | 2013-06-21 | 2015-04-07 | Gnt Llc | Ophthalmic lipophilic drug delivery vehicle formulations |
CA2926515C (en) | 2013-10-31 | 2020-11-24 | Allergan, Inc. | Prostamide-containing intraocular implants and methods of use thereof |
WO2015097600A2 (en) | 2013-12-24 | 2015-07-02 | Sentiss Pharma Private Limited | Topical brimonidine tartrate ophthalmic solution |
EP3270892B1 (en) * | 2015-03-19 | 2024-04-10 | Allergan, Inc. | Fixed dose combination of brimonidine and timolol |
EP3496662A4 (en) | 2016-08-12 | 2019-10-30 | Silk Technologies Ltd. | PROTEIN DERIVED FROM SILK FOR THE TREATMENT OF INFLAMMATION |
AU2020264808A1 (en) | 2019-05-01 | 2021-11-04 | Clexio Biosciences Ltd. | Methods of treating pruritus |
KR20240045074A (ko) | 2022-09-29 | 2024-04-05 | 주식회사태준제약 | 브리모니딘을 포함하는 안과용 조성물 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1197391A (zh) * | 1995-06-28 | 1998-10-28 | 阿勒根 | 应用(2-咪唑啉-2-基氨基)喹喔啉治疗视神经损伤的方法 |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL286080A (zh) * | 1961-11-30 | |||
US3278447A (en) | 1963-12-02 | 1966-10-11 | Cloro Bac Products Inc | Process for stabilizing chlorine dioxide solution |
BE795970A (fr) | 1972-02-29 | 1973-08-27 | Pfizer | Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant |
US4530920A (en) | 1983-11-07 | 1985-07-23 | Syntex (U.S.A.) Inc. | Nonapeptide and decapeptide analogs of LHRH, useful as LHRH agonist |
US4806556A (en) | 1985-12-12 | 1989-02-21 | Regents Of The University Of Minnesota | Gut-selective opiates |
US5719197A (en) | 1988-03-04 | 1998-02-17 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
US5607698A (en) | 1988-08-04 | 1997-03-04 | Ciba-Geigy Corporation | Method of preserving ophthalmic solution and compositions therefor |
US5202128A (en) | 1989-01-06 | 1993-04-13 | F. H. Faulding & Co. Limited | Sustained release pharmaceutical composition |
CA2007181C (en) | 1989-01-06 | 1998-11-24 | Angelo Mario Morella | Sustained release pharmaceutical composition |
JPH085779B2 (ja) * | 1989-09-22 | 1996-01-24 | 杏林製薬株式会社 | フレロキサシン点眼液 |
US5352796A (en) | 1989-10-30 | 1994-10-04 | The Salk Institute For Biological Studies | Amino acids useful in making GnRH analogs |
US5021416A (en) * | 1989-10-31 | 1991-06-04 | Allergan, Inc. | Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure |
US5215991A (en) * | 1990-01-26 | 1993-06-01 | Allergan, Inc. | Combination of selective alpha-adrenergic agonists and Na+ /H+ ex |
GB9017353D0 (en) | 1990-08-08 | 1990-09-19 | Merck Sharp & Dohme | Chemical process |
IT1252692B (it) * | 1991-11-27 | 1995-06-23 | Zambon Spa | Composizione farmaceutica per uso oftalmico contenente un antiinfiammatorio non steroideo ed un decongestionante come principi attivi |
JPH05271053A (ja) * | 1992-03-27 | 1993-10-19 | Lion Corp | 安定な点眼剤 |
US5459133A (en) * | 1992-06-05 | 1995-10-17 | Telor Ophthalmic Pharmaceuticals, Inc. | Methods and products for treating presbyopia |
AU6124494A (en) | 1993-01-28 | 1994-08-15 | University Of Iowa Research Foundation, The | Ophthalmic uses of signa agonists |
JP3683908B2 (ja) | 1993-10-13 | 2005-08-17 | アラーガン、インコーポレイテッド | (2−イミダゾリン−2−イルアミノ)キノキサリン誘導体の使用方法 |
US5994110A (en) | 1995-02-10 | 1999-11-30 | Mosbach; Klaus | Methods for direct synthesis of compounds having complementary structure to a desired molecular entity and use thereof |
US6294563B1 (en) * | 1994-10-27 | 2001-09-25 | Allergan Sales, Inc. | Combinations of prostaglandins and brimonidine or derivatives thereof |
ZA965837B (en) | 1995-07-11 | 1997-01-31 | Merck & Co Inc | A triazolylmethyl-indole ethylamine bisulfate salt |
EP0834308A1 (en) | 1996-09-30 | 1998-04-08 | LG Chemical Limited | Ophthalmic formulation for treating myopia comprising dopamine agonist and cyclodextrin |
JP2001522358A (ja) | 1997-04-18 | 2001-11-13 | アボツト・ラボラトリーズ | 高純度6,7−ジクロロ−5−ニトロ−2,3−ジヒドロキノキサリン−2,3−ジオンの調製方法 |
MY116782A (en) * | 1997-12-22 | 2004-03-31 | Otsuka Pharma Co Ltd | Water-soluble eye drop |
AU2870899A (en) | 1998-02-26 | 1999-09-15 | Abbott Laboratories | Oral formulation for hydrophilic drugs |
CA2322579C (en) | 1998-04-07 | 2001-08-28 | Alcon Laboratories, Inc. | Gelling ophthalmic compositions containing xanthan gum |
JP2002523475A (ja) * | 1998-09-02 | 2002-07-30 | アラーガン・セイルズ・インコーポレイテッド | 防腐したシクロデキストリン含有組成物 |
ATE289804T1 (de) | 1998-10-08 | 2005-03-15 | Hampar L Karagoezian | Synergistische antimikrobielle. dermatologische und ophtahalmologische zubereitungen, die ein chlorit und wasserstoffperoxid enthalten |
IN185228B (zh) * | 1999-02-03 | 2000-12-09 | Bakulesh Mafatlal Dr Khamar | |
JP2004503593A (ja) * | 2000-07-14 | 2004-02-05 | アラーガン、インコーポレイテッド | 増大した溶解度を持つ治療活性成分を含む組成物 |
AU2001273269B2 (en) * | 2000-07-14 | 2005-08-11 | Allergan, Inc. | Compositions containing alpha-2-adrenergic agonist components |
-
2001
- 2001-07-09 AU AU2001273269A patent/AU2001273269B2/en not_active Expired
- 2001-07-09 PL PL36070701A patent/PL360707A1/xx not_active Application Discontinuation
- 2001-07-09 KR KR1020027014270A patent/KR100757656B1/ko active IP Right Grant
- 2001-07-09 NZ NZ521185A patent/NZ521185A/en not_active IP Right Cessation
- 2001-07-09 BR BR0109317-7A patent/BR0109317A/pt not_active Application Discontinuation
- 2001-07-09 HU HU0303197A patent/HUP0303197A3/hu not_active Application Discontinuation
- 2001-07-09 EP EP01952528A patent/EP1365811A2/en not_active Ceased
- 2001-07-09 IL IL15153001A patent/IL151530A0/xx unknown
- 2001-07-09 CN CNB018073395A patent/CN100569291C/zh not_active Expired - Lifetime
- 2001-07-09 WO PCT/US2001/021552 patent/WO2002005853A2/en active IP Right Grant
- 2001-07-09 MX MXPA02008930A patent/MXPA02008930A/es active IP Right Grant
- 2001-07-09 CA CA002402405A patent/CA2402405C/en not_active Expired - Lifetime
- 2001-07-09 CN CN200910247188.9A patent/CN101897704B/zh not_active Expired - Lifetime
- 2001-07-09 RU RU2003101321/15A patent/RU2311928C2/ru active
- 2001-07-09 JP JP2002511784A patent/JP4927298B2/ja not_active Expired - Lifetime
- 2001-07-09 AU AU7326901A patent/AU7326901A/xx active Pending
- 2001-07-10 US US09/904,018 patent/US6627210B2/en not_active Expired - Lifetime
- 2001-07-13 AR ARP010103344A patent/AR033539A1/es not_active Application Discontinuation
- 2001-07-13 TW TW090117220A patent/TWI287998B/zh not_active IP Right Cessation
-
2002
- 2002-08-28 IL IL151530A patent/IL151530A/en unknown
- 2002-09-04 NO NO20024221A patent/NO333367B1/no not_active IP Right Cessation
- 2002-09-06 US US10/236,566 patent/US6641834B2/en not_active Expired - Lifetime
- 2002-09-16 ZA ZA200207413A patent/ZA200207413B/en unknown
- 2002-11-19 US US10/299,386 patent/US6673337B2/en not_active Expired - Lifetime
-
2003
- 2003-10-22 US US10/691,912 patent/US20040063689A1/en not_active Abandoned
-
2004
- 2004-05-18 HK HK04103520.9A patent/HK1060519A1/xx not_active IP Right Cessation
-
2008
- 2008-06-02 JP JP2008144707A patent/JP2008231122A/ja active Pending
-
2011
- 2011-12-27 JP JP2011286579A patent/JP2012067128A/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1197391A (zh) * | 1995-06-28 | 1998-10-28 | 阿勒根 | 应用(2-咪唑啉-2-基氨基)喹喔啉治疗视神经损伤的方法 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101897704B (zh) | 含有α-2肾上腺素能激动剂的组合物 | |
AU2001273269A1 (en) | Compositions containing alpha-2-adrenergic agonist components | |
JP2004503593A (ja) | 増大した溶解度を持つ治療活性成分を含む組成物 | |
JP2012246304A (ja) | α−2−アドレナリンアゴニスト成分を含有する組成物 | |
US20200069576A1 (en) | Compositions containing alpha-2-adrenergic agonist components | |
US20040214829A1 (en) | Compositions containing alpha-2-adrenergic agonist components | |
AU2005220199B2 (en) | Compositions containing alpha-2-adrenergic agonist components | |
CA2474280C (en) | Compositions containing alpha-2-adrenergic agonist components | |
AU2007202599B2 (en) | Compositions containing alpha-2-adrenergic agonist components | |
AU2011250793B2 (en) | Compositions containing alpha-2-adrenergic agonist components |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CX01 | Expiry of patent term |
Granted publication date: 20141029 |
|
CX01 | Expiry of patent term |